Eli Lilly and Company (LLY)
NYSE · Healthcare · Drug Manufacturers - General
Profile
Eli Lilly and Company
- Exchange
- NYSE
- Ticker
- LLY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- US
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Key facts
Eli Lilly and Company: key facts
- Eli Lilly and Company (NYSE: LLY) is a Drug Manufacturers - General company in the Healthcare sector.
- In fiscal 2025, Eli Lilly and Company reported revenue of $65.2B and net income of $20.6B.
- Revenue grew 23.2% a year over the last 4 fiscal years.
- Free cash flow was positive in 4 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $86.5B and net income was $27.6B.
MonkScore
Eli Lilly and Company's MonkScore
MonkScore
MonkScore range: 90–100
as of October 2026
Sector rank: 22 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth90–100
- Profitability80–90
- Quality70–80
- Market Conviction90–100
- Safety50–60
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Eli Lilly and Company's annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $86.5B | $65.2B | $45.0B | $34.1B | $28.5B | $28.3B |
| Gross profit | $72.3B | $54.1B | $36.6B | $27.0B | $21.9B | $21.0B |
| Operating income | $39.8B | $29.7B | $17.0B | $10.8B | $8.7B | $7.9B |
| Net income | $27.6B | $20.6B | $10.6B | $5.2B | $6.2B | $5.6B |
| Operating cash flow | $30.6B | $16.8B | $8.8B | $4.2B | $7.6B | $7.4B |
| Capital expenditure | -$11.0B | -$7.8B | -$5.1B | -$7.4B | -$3.0B | -$2.0B |
| Free cash flow | $19.7B | $9.0B | $3.8B | -$3.2B | $4.6B | $5.4B |
| Total debt | $49.5B | $42.5B | $33.6B | $25.2B | $16.2B | $16.9B |
| Cash | $4.9B | $7.2B | $3.3B | $2.8B | $2.1B | $3.8B |
Revenue growth a year
- 1-year
- 44.7%
- 3-year
- 31.7%
- 4-year
- 23.2%
Compound growth between fiscal years.
Peers
Similar companies
- Gilead Sciences, Inc.NASDAQ:GILDMonkScore range: 90–100
- AbbVie Inc.NYSE:ABBVMonkScore range: 90–100
- Amgen Inc.NASDAQ:AMGNMonkScore range: 90–100
- Bristol-Myers Squibb CompanyNYSE:BMYMonkScore range: 80–90
- Johnson & JohnsonNYSE:JNJMonkScore range: 70–80
- Organon & Co.NYSE:OGNMonkScore range: 60–70
- Merck & Co., Inc.NYSE:MRKMonkScore range: 60–70
- Biogen Inc.NASDAQ:BIIBMonkScore range: 50–60
Compare
Compare with
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
Free tools for Eli Lilly and Company: Dividend calculator
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.